Breakthrough Alzheimer's Drug Receives Government Approval, Faces Challenges Ahead

The FDA has granted full approval for a new Alzheimer's drug developed by Biogen and Eisai, paving the way for Medicare coverage and increased patient access. However, the road ahead remains challenging, as the drug faces burdensome caveats, including close patient monitoring and data collection for adverse events. The high costs of the treatment could also pose political challenges and competition from other drugs. Despite these obstacles, Wall Street remains cautiously optimistic, with some analysts highlighting potential upside for healthcare companies involved in home infusion services.